is trulicity a glp-1 receptor agonists Dual and Triple Gut Peptide on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports glp-1_analogs [TUSOM | Pharmwiki]

The incretin effect was estimated to account for approximately 50% - 70% of the postprandial insulin responses in healthy individuals and may be substantially reduced to 20% 30% in individuals with type 2 diabetes mellitus (T2DM) (6, 7), a complex disorder arising from inadequate compensation of insulin secretion by pancreas to counter peripheral insulin resistance

(2024) 7:e2427258

Received 2021-3-1

2023 Accessed March 9, 2023

However, continuous research and vigilant monitoring are essential to optimize their safe use [55] [56], particularly as these medications are used in broader populations for longer durations

Because digestion slows on these medications, a sudden spike in fiber can lead to bloating, burping, or gas